Foundation Medicine was founded in 2010 with a mission to bring deep molecular information to the point of care for every patient living with advanced cancer.

We’re an essential partner to patients, physicians, researchers, and biopharma organizations navigating the complex landscape of cancer care. Our genomic insights help guide informed decisions about treatment plans and research priorities.

Over the past decade, we’ve partnered with researchers, biopharma, advocacy organizations, government bodies, health plans, and regulators to validate the use of genomic testing in clinical care, drive awareness among patients and physicians and ultimately support broader access for patients.

The answers we provide through our testing are essential first steps in developing informed treatment strategies and accelerating the development of transformative new therapies.

When cancer leaves our customers and their patients in the dark, NeoGenomics is here to light the way. For over 20 years, we’ve built our business around complex cancer insights, uniquely positioned to help our partners break new ground as they navigate the increasingly complex disease landscape — allowing patients to arrive at transformative care plans that help save lives. Wherever you are on the cancer care continuum, our industry-leading testing and information solutions will guide you toward a brighter future in tackling cancer.

At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater VALUE by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.

Our human health care mission, the desire to contribute to patients, is our corporate philosophy and the core of our business. Established in 1992, the hhc philosophy is a common value among all employees worldwide. Spending time with patients and understanding their true needs has become the source of Eisai’s innovation.

With the introduction of EWAY 2025, our medium-term business plan, we updated our patient socialization program to include internal innovation training and enhance our commitment.

Also in EWAY 2025, Eisai selected two therapeutic areas of focus: neurology and oncology. In these areas, we believe it is important to find “Ricchi” – a Japanese term that means finding a place “where real patient needs are still unmet; where Eisai can become a frontrunner.”

We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We discover, develop, manufacture and deliver innovative medicines to help millions of patients. Amgen helped establish the biotechnology industry more than 40 years ago and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.

At Takeda Oncology, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.

We know that our mission is not a quick or simple one, but we are up for the task:

We aspire to cure cancer.

Servier US, a commercial-stage, privately held pharmaceutical company, is a leader in oncology and is building up its neurology business, focused on addressing rare diseases and unmet patient needs with a commitment to delivering innovative therapies.

The American Cancer Society is the leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. We are the only organization working to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.

We provide the support and guidance people impacted by cancer need at every step – from increasing access to screening at the local, state, and federal levels and advocating for more affordable health care to guiding patients and caregivers through our free 24/7 helpline and helping them get the treatment they need by offering free transportation and lodging. In addition, we fund and conduct research so people in every community have the opportunity to prevent, detect, treat and survive cancer.

The mission of the American Cancer Society is to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Co., Ltd., is headquartered in Basking Ridge, New Jersey, and is focused on the development and delivery of oncology and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for metastatic breast, lung and gastric cancer, tenosynovial giant cell tumor and iron deficiency anemia. Visit us at www.daiichisankyo.us.

AI-enabled precision medicine: Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

ADC Therapeutics is a leading, commercial-stage global pioneer in the field of antibody drug conjugates (ADCs).

Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors.

Our senior leaders are industry veterans with experience in both large pharmaceutical companies and biotechnology startups and our highly skilled global workforce is committed to transforming the lives of patients with cancer.

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives.

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.